Winner Medical(SZ:300888) Guotou Securities·2026-02-25 11:39Investment Rating - The report maintains a "Buy-A" investment rating for the company, with a target price of 46.75 CNY based on a 19x PE for 2026 [3][5]. Core Insights - The company's growth strategy for 2026 is clearly defined, focusing on a dual-driven approach of "medical + consumer" sectors, aiming to enhance efficiency and expand market presence [1]. - The medical segment's growth will be driven by both internal structural optimization and external acquisitions, particularly highlighting the acquisition of the US-based GRI company, which is expected to significantly boost revenue starting in 2025 [1]. - The consumer segment's growth is primarily fueled by brand strength and category expansion, with a focus on high-repurchase-rate products such as maternal and infant care items [1][2]. Summary by Sections Company Overview - The company is positioned to leverage its dual-driven strategy to enhance profitability and market share in both medical and consumer sectors [1]. Financial Performance - In Q3 2025, the company reported a revenue of 2.6 billion CNY, a year-on-year increase of 27.7%, and a net profit of 240 million CNY, up 42.1% year-on-year [2]. - The medical segment benefited from overseas market expansion, with foreign sales channels increasing by 81.7% year-on-year [2]. Future Projections - Revenue projections for 2025-2027 are estimated at 10.368 billion CNY, 12.156 billion CNY, and 14.274 billion CNY, representing growth rates of 15.49%, 17.24%, and 17.42% respectively [3][6]. - Net profit forecasts for the same period are 1.071 billion CNY, 1.433 billion CNY, and 1.871 billion CNY, with growth rates of 54.01%, 33.78%, and 30.56% respectively [3][6].